Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | ESRRA | P11474 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.63 |
| ▸ | PGR | P06401 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | ESRRB | O95718 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.63 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.63 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2854638 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL8505904 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL2854643 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL24103220 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL16485139 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL24103217 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL14569768 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL24583080 | 1.00 | ESR1 (0.63) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL13301006 | 0.89 | ESR1 (0.50) | ESR1ESR2LMNAHSD17B10ESRRA | |
| SCHEMBL14540439 | 0.89 | ESR1 (0.65) | ESR1ESR2LMNAHSD17B10ESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180050046-A1 | FULVESTRANT FORMULATIONS | FRESENIUS KABI USA, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-9833459-B2 | Fulvestrant formulations | FRESENIUS KABI USA, LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160129014-A1 | FULVESTRANT FORMULATIONS | FRESENIUS KABI USA, LLC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9315540-B2 | Process for the preparation of fulvestrant | INTAS PHARMACEUTICALS LTD. (IN) | 2016-04-19 | — | — | US | disclosed |
| US-9271990-B2 | Fulvestrant formulations | FRESENIUS KABI USA, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150291652-A1 | PROCESS FOR THE PREPARATION OF FULVESTRANT | INTAS PHARMACEUTICALS LTD. (IN) | 2015-10-15 | — | — | US | disclosed |
| US-20150231153-A1 | FULVESTRANT FORMULATIONS | FRESENIUS KABI USA LLC | 2015-08-20 | — | — | US | disclosed |
| WO-2012035516-A1 | FULVESTRANT COMPOSITIONS AND METHODS OF USE | SWART HENK (ZA) | 2012-03-22 | — | — | WO | disclosed |
| US-8017735-B2 | Comprising one or more binding compositions comprising a member selected from a light chain amino acid sequence which comprises CDR-L1 and a heavy chain amino acid sequence which comprises CDR-H1 in association with one or more chemotherapeutic agents; cancer therapy | SCHERING CORPORATION (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100048523-A1 | Compounds, Compositions and Methods for Treating Hormone-Dependent Maladies | THE JOHNS HOPKINS UNIVERSITY | 2010-02-25 | — | — | US | disclosed |
| WO-2009111057-A2 | FULVESTRANT FORMULATIONS | SCIDOSE LLC (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20080242648-A1 | COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | SYNDAX PHARMACEUTICALS, INC., A CALIFORNIA CORPORATION (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242648-A1 | COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | SYNDAX PHARMACEUTICALS, INC., A CALIFORNIA CORPORATION (US) | 2008-10-02 | — | — | US | disclosed |
| WO-2007044662-A2 | SEPARATION OF FULVESTRANT ISOMERS | SICOR, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291652-A1 | PROCESS FOR THE PREPARATION OF FULVESTRANT | CYP19A1, NR5A1, HSD17B11 | ESR1 5/4885ESR2 16/4885LMNA 1949/4885 |
| US-20100048523-A1 | Compounds, Compositions and Methods for Treating Hormone-Dependent Maladies | CYP21A2, CYP17A1, NR5A1 | ESR1 1553/4885ESR2 1037/4885LMNA 1790/4885 |
| US-20080242648-A1 | COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | HDAC3, HDAC1, NCOA1 | ESR1 10/4885ESR2 5/4885LMNA 1806/4885 |
| US-20160129014-A1 | FULVESTRANT FORMULATIONS | NR5A1, ESRRA, PGR | ESR1 6/4885ESR2 14/4885LMNA 4467/4885 |
| US-20150231153-A1 | FULVESTRANT FORMULATIONS | NR5A1, ESRRA, PGR | ESR1 6/4885ESR2 14/4885LMNA 4467/4885 |
| US-20180050046-A1 | FULVESTRANT FORMULATIONS | PGR, ESR1, GNRHR | ESR1 2/4885ESR2 14/4885LMNA 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.